BENCHMARKS FOR ABNORMAL SCREENING MAMMOGRAPHY INTERPRETATIONS,
BASED ON BCSC DATA, 2007 - 2013 *
Recall Rate
| Number of Screening Exams | |
|---|---|
| Recall rate (RR)‡ | 11.50% |
| Readers with 1000+ examinations | 249 |
| Abnormal initial interpretations | 189,682 |
| All examinations | 1,642,690 |
| RR (Median - 50th percentile) | 10.8 |
| RR (25th, 75th percentiles) | 8.4, 14.7 |
| RR (10th, 90th percentiles) | 6.3, 18.0 |
SMOOTHED PLOT OF Recall Rate FREQUENCY DISTRIBUTION+
FOR 1,642,690 SCREENING MAMMOGRAMS (AMONG RADIOLOGISTS WITH 1000+ EXAMS)
Positive Predictive Value 1 (PPV1)
| Number of Screening Exams | |
| PPV1§ | 4.40% |
| Readers with 100+ abnormal interpretations | 255 |
| Cancers | 8,362 |
| Abnormal initial interpretations | 191,026 |
| PPV1 (Median - 50th percentile) | 4.4 |
| PPV1 (25th, 75th percentiles) | 3.2, 5.7 |
| PPV1 (10th, 90th percentiles) | 2.5, 7.4 |
Smoothed Plot of PPV1 Frequency Distribution+
FOR 191,026 SCREENING MAMMOGRaMS WITH ABNORMAL INITIAL INTERPRETATIONS (AMONG RADIOLOGISTS WITH 100+ EXAMS WITH ABNORMAL INITIAL INTERPRETATIONS)
Positive Predictive Value 2 (PPV2)
| Number of Screening Exams | |
| PPV2|| | 25.20% |
| Readers with 30+ biopsies recommended | 172 |
| Cancers | 6,893 |
| Abnormal final interpretations | 27,358 |
| PPV2 (Median - 50th percentile) | 26.1 |
| PPV2 (25th, 75th percentiles) | 19.8, 35.6 |
| PPV2 (10th, 90th percentiles) | 16.7, 42.3 |
SMOOTHED Plot of PPV2 Frequency Distribution+
FOR 27,358 SCREENING MAMMOGRAMS WITH ABNORMAL FINAL INTERPRETATIONS FOR WHICH BIOPSY WAS RECOMMENDED (AMONG RADIOLOGISTS WITH 30+ BIOPSIES RECOMMENDED)
Positive Predictive Value 3 (PPV3)
| Number of Screening Exams | |
| PPV3# | 27.90% |
| Readers with 30+ biopsies performed | 125 |
| Cancers | 5,414 |
| Abnormal final interpretations, with known biopsy | 19,389 |
| PPV3 (Median - 50th percentile) | 31.1 |
| PPV3 (25th, 75th percentiles) | 23.0, 39.7 |
| PPV3 (10th, 90th percentiles) | 19.4, 46.6 |
Smoother Plot of PPV3 Frequency Distribution+
FOR 19,389 SCREENING MAMMOGRAMS WITH ABNORMAL FINAL INTERPRETATION FOR WHICH BIOPSY WAS RECOMMENDED AND PERFORMED (AMONG RADIOLOGISTS WITH 30+ BIOPSIES PERFORMED)
Footnotes:
Numbers are frequencies unless otherwise indicated.
Screening mammography examinations: mammography examinations indicated by the radiologist to be for screening, with bilateral routine views done and no other mammogram within the last 9 months, among women without breast implants.
* Includes examinations for radiologists with minimum numbers of cases as designated; excludes examinations for which the radiologist is unknown.
‡ Recall rate = the percentage of examinations with an abnormal initial interpretation (BI-RADS category 0, 4, or 5; Note: 3 with a recommendation for immediate follow-up was recoded as 0.)
§ PPV1 = the percentage of examinations with an abnormal initial interpretation that result in a tissue diagnosis of cancer within 1 year.
|| PPV2 = the percentage of examinations with an abnormal final interpretation** that result in a tissue diagnosis of cancer within 1 year.
# PPV3 = the percentage of examinations with an abnormal final interpretation**, where it is known that a biopsy was performed as a result of the abnormal diagnostic examination, that result in a tissue diagnosis of cancer within 1 year. (Excludes Chicago)
** Abnormal final interpretation (BI-RADS category 4 or 5: Note: 0 or 3 with a recommendation for biopsy was recoded as 4).
+ For figures, An overlaid solid line indicates the 50th percentile (median), paired dashed lines indicate the 25th and 75th percentiles, and paired dotted lines indicate the 10th and 90th percentiles. A single dashed line below the median indicates the 10th and 25th percentiles are the same and a single dashed line above the median indicates the 75th and 90th percentiles are the same.
Tables & figures numbers last updated March 23, 2017 .
The following must be cited when reproducing this data:
"The Breast Cancer Surveillance Consortium and its data collection and sharing activities are funded by the National Cancer Institute (P01CA154292). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - http://www.bcsc-research.org/. More information regarding the BCSC is available at: http://bcsc-research.org/."